US obesity intervention market

The rise of GLP-1 receptor agonists is significantly transforming the landscape of obesity treatment, impacting the growth of bariatric procedures and affecting device sales. Innovations and future reimbursements in the GLP-1 space are expected to continue placing downward pressure on the demand for bariatric procedures. Despite this, the growing obese population and increased treatment rates are anticipated to drive the obesity intervention market. Additionally, less-invasive endoluminal procedures and the adoption of innovative technologies that command higher prices will contribute to sustaining the obesity intervention market.
Read our Market Snapshot to access data and analysis on the state of the obesity intervention market in the US from 2019 through 2034.